Visual hallucinations in Parkinson's disease: spotlight on central cholinergic dysfunction.
Anna Ignatavicius1, Elie Matar1,2,3, Simon J G Lewis4,5
1Faculty of Medicine and Health, Central Clinical School, University of Sydney, Sydney, NSW 2050, Australia.
Brain : a Journal of Neurology
|September 10, 2024
Summary
Visual hallucinations in Parkinson's disease are linked to brain changes. Cholinergic system dysfunction is a key factor, offering new avenues for treatment.
Area of Science:
- Neuroscience
- Neurology
Background:
- Visual hallucinations are a common, debilitating non-motor symptom in Parkinson's disease (PD).
- These hallucinations are associated with significant negative outcomes, including cognitive decline and increased mortality.
- Current treatment options for visual hallucinations in PD are limited.
Purpose of the Study:
- To explore the role of cholinergic system dysfunction in the development of visual hallucinations in Parkinson's disease.
- To propose a neurobiological framework for understanding these hallucinations.
- To identify potential therapeutic targets based on cholinergic pathways.
Main Methods:
- Review of existing literature on the neurobiology of visual hallucinations in PD.
- Analysis of theoretical models linking cognitive processes to cholinergic neurotransmission.
- Synthesis of evidence implicating central cholinergic system degeneration.
Main Results:
- Convergent evidence suggests degeneration in the central cholinergic system is a significant factor in visual hallucinations.
- Alterations in cholinergic neurotransmission impact cognitive processes crucial for perception.
- Cholinergic dysfunction may provide a unifying explanation for the complex nature of these hallucinations.
Conclusions:
- Cholinergic neurobiology is a critical area for understanding visual hallucinations in Parkinson's disease.
- Targeting cholinergic pathways may improve treatments for hallucinations and psychosis in PD.
- Further research into individual pathophysiology can refine therapeutic strategies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
237
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
237
01:15Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
638
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
638
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
01:26Cholinergic Antagonists: Therapeutic Uses
730
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
730